Skip to Content

Join the 'Revlimid' group to help and get support from people like you.

Revlimid News

Drug Trio Shows Major Promise Against Myeloma

Posted 6 Oct 2016 by Drugs.com

THURSDAY, Oct. 6, 2016 – Adding a newer drug to a standard treatment for advanced cases of multiple myeloma may significantly boost patients' chances of a response and even recovery, a new clinical trial finds. Of patients given the drug, called daratumumab, 43 percent had a complete response – meaning there were no signs of the cancer left. That compared with 19 percent of patients who received a standard drug duo alone. And over 13.5 months, the daratumumab combination cut patients' risk of dying or seeing their cancer progress by 63 percent, the study found. Researchers called the results "unprecedented" for patients like these. All had relapsed or refractory myeloma – which means the cancer had either come back or failed to respond to the previous treatment. "It is very likely that (this regimen) will be rapidly adopted by practicing physicians," said lead researcher Dr. Meletios ... Read more

Related support groups: Dexamethasone, Multiple Myeloma, Revlimid, Decadron, TobraDex, Ciprodex, Maxitrol, Osteolytic Bone Lesions of Multiple Myeloma, Ozurdex, Dexamethasone/Tobramycin, Tobradex ST, Dexamethasone/Neomycin/Polymyxin B, Lenalidomide, Decadron Tablets, Dexamethasone/Neomycin, Adrenocot, Maxidex, Poly-Dex, Decadron Dose Pack, Dexone

U.S. Pays Highest Prices for Cancer Meds: Study

Posted 6 Jun 2016 by Drugs.com

MONDAY, June 6, 2016 – The United States pays the highest prices in the world for generic and brand-name cancer drugs, a new study has found. However, as the world's wealthiest nation, the United States is better able to pay for those pricey drugs than poorer countries with somewhat lower medication prices, added study lead author Dr. Daniel Goldstein. People in China and India are much less able to afford cancer drugs than Americans, he said, even though U.S. monthly drug prices are about three to six times higher in the United States. That doesn't mean America came out on top in overall drug affordability, however. Developed nations such as Australia, England and Israel had the "best deal" in the world on cancer drugs, thanks to government programs that regulate drug pricing, the study found. "America is the wealthiest nation, but its drug prices are significantly higher – so much ... Read more

Related support groups: Cancer, Provera, Depo-Provera, Methotrexate, Breast Cancer, Accutane, Lupron, Tamoxifen, Medroxyprogesterone, Arimidex, Tretinoin, Fluorouracil, Femara, Lupron Depot, Gleevec, Lung Cancer, Colorectal Cancer, Isotretinoin, Rituxan, Claravis

'Precision' Cancer Treatment May Extend Lives

Posted 20 May 2016 by Drugs.com

THURSDAY, May 19, 2016 – "Precision" cancer treatment that's guided by genetic clues from the patient's own tumor appears to outperform traditional chemotherapy, a new research review finds. Patients given precision – or personalized – treatment experienced a tumor shrinkage rate six times that attained by regular chemotherapy. But, that only happened if doctors used genetic information to choose the appropriate targeted therapy, said lead researcher Maria Schwaederle. Those patients also experienced nearly double the length of time before their cancer resumed growing, according to the analysis of nearly 350 clinical trials. "It is not just that the therapies are better, but that targeted therapies must be given to the right patients," said Schwaederle, who's with the University of California, San Diego School of Medicine's Center for Personalized Cancer Therapy. She will present ... Read more

Related support groups: Cancer, Methotrexate, Breast Cancer, Accutane, Tretinoin, Fluorouracil, Gleevec, Lung Cancer, Colorectal Cancer, Isotretinoin, Claravis, Tarceva, Xeloda, Skin Cancer, BCG, Revlimid, Tasigna, Sprycel, Hydroxyurea, Zytiga

Kidney Woes Tied to Raised Cancer Risk, Study Finds

Posted 12 Nov 2015 by Drugs.com

THURSDAY, Nov. 12, 2015 – Kidney failure and having a kidney transplant may increase the risk for certain types of cancer, a new study suggests. Poor kidney function and immune system-suppressing drugs may be behind this increased risk, according to Elizabeth Yanik, of the U.S. National Cancer Institute, and colleagues. For the study, published in the Nov. 12 online edition of the Journal of the American Society of Nephrology, the researchers looked at data from more than 200,000 U.S. kidney transplant candidates and recipients. Along with finding that these patients are at increased risk for certain types of cancer, the investigators also identified clear patterns of risk associated with different types of treatment. However, the associations seen in the study do not prove cause-and-effect. The risk of kidney and thyroid cancers was especially high when kidney failure patients were on ... Read more

Related support groups: Cancer, Methotrexate, Renal Failure, CellCept, Gilenya, Tysabri, Xolair, Imuran, Orencia, Chronic Kidney Disease, Revlimid, Arava, Leflunomide, Azathioprine, Afinitor, Tecfidera, Mycophenolate Mofetil, Peritoneal dialysis, Aubagio, Benlysta

U.S. Oncologists Decry High Cost of Cancer Drugs

Posted 23 Jul 2015 by Drugs.com

THURSDAY, July 23, 2015 – Soaring costs for cancer drugs are hurting patient care in the United States, a group of top oncologists claim. "High cancer-drug prices are affecting the care of patients with cancer and our health care system," Dr. Ayalew Tefferi, a hematologist at Mayo Clinic in Rochester, Minn., said in a Mayo news release. Tefferi and his colleagues made a number of recommendations on how to address the problem in a commentary published July 23 in the Mayo Clinic Proceedings. Allowing Medicare to negotiate drug prices is one of the suggestions the team of 118 leading cancer experts offered as a possible solution. Along with their recommendations, the group also expressed support for a patient-based grassroots movement on change.org that is demanding action on the issue. "The average gross household income in the U.S. is about $52,000 per year. For an insured patient with ... Read more

Related support groups: Cancer, Provera, Depo-Provera, Methotrexate, Breast Cancer, Accutane, Lupron, Prostate Cancer, Tamoxifen, Medroxyprogesterone, Arimidex, Tretinoin, Fluorouracil, Lupron Depot, Femara, Gleevec, Lung Cancer, Colorectal Cancer, Renal Cell Carcinoma, Isotretinoin

New Drug Shows Potential for Blood Cancer

Posted 2 Jun 2015 by Drugs.com

TUESDAY, June 2, 2015 – A two-pronged immune-boosting drug could provide new hope for people stricken with multiple myeloma, a cancer of the blood and bone marrow, according to clinical trial findings. The experimental drug, elotuzumab, reduced the risk of cancer progression and death by 30 percent when doctors combined it with the standard two-drug therapy for multiple myeloma, researchers found. Elotuzumab works against this relatively rare cancer through a dual mechanism, said senior study author Dr. Sagar Lonial. It makes cancer cells vulnerable to immune attack, and also enhances the immune system's ability to kill cancer. "It's a bit of a double-whammy," said Lonial, executive vice chair of hematology and oncology at Emory University School of Medicine in Atlanta. Patients receiving the three-drug elotuzumab cocktail did not seem to suffer an increase in side effects, compared ... Read more

Related support groups: Revlimid, Multiple Myeloma, Lenalidomide

FDA Expands Indication for Revlimid (lenalidomide) in Combination with Dexamethasone to Include Patients Newly Diagnosed with Multiple Myeloma

Posted 18 Feb 2015 by Drugs.com

SUMMIT, N.J., February 18, 2015 --(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) today announced that the U.S. Food and Drug Administration (FDA) has expanded the existing indication for Revlimid (lenalidomide) in combination with dexamethasone to include patients newly diagnosed with multiple myeloma (NDMM). Revlimid plus dexamethasone was previously approved in June 2006 for use in multiple myeloma patients who have received at least one prior therapy. "The approval of Revlimid as an option for use in all patients with multiple myeloma represents a new paradigm in the management of this disease," said Kenneth Anderson, M.D., Director, Jerome Lipper Multiple Myeloma Center, Dana-Farber/Brigham and Women's Cancer Center. "We now have clinical evidence demonstrating that starting and keeping newly diagnosed multiple myeloma patients on Revlimid significantly improves ... Read more

Related support groups: Revlimid, Multiple Myeloma, Lenalidomide

Too Few Prostate Cancer Patients Get Bone-Strengthening Meds: Study

Posted 3 Dec 2014 by Drugs.com

TUESDAY, Dec. 2, 2014 – Many men on hormone therapy for prostate cancer aren't getting bone-strengthening drugs they may need, new Canadian research contends. Hormone therapy, which suppresses male hormones called androgens, helps stop cancer cells from growing. But one consequence of the treatment is weakening of the bones, which can lead to fractures. To reduce this risk, men can be given oral bisphosphonates, such as Fosamax, or an intravenous treatment once a month or once a year with similar drugs, such as Reclast. "There seems to be a clear mismatch between Canadian guidelines regarding bisphosphonate usage in men undergoing hormone therapy for prostate cancer and actual clinical practice," said lead researcher Dr. Shabbir Alibhai, a senior scientist at the University Health Network in Toronto. While the low rates of bisphosphonate prescriptions may be appropriate for patients ... Read more

Related support groups: Provera, Depo-Provera, Accutane, Lupron, Prostate Cancer, Tamoxifen, Medroxyprogesterone, Fosamax, Arimidex, Tretinoin, Femara, Lupron Depot, Boniva, Isotretinoin, Alendronate, Claravis, Anastrozole, Reclast, Evista, Zoladex

Medicines Are Biggest Culprit in Fatal Allergic Reactions: Study

Posted 10 Oct 2014 by Drugs.com

THURSDAY, Oct. 9, 2014 – Although food allergies have garnered a lot of attention lately, a new study reports that medications are actually the biggest cause of sudden deaths related to allergy. Over a little more than a decade, nearly 60 percent of the allergy-related deaths were caused by medications, while less than 7 percent were caused by food allergies, the study found. "Medications can be dangerous," said study researcher Dr. Elina Jerschow, director of the Drug Allergy Center at Montefiore Medical Center and assistant professor of medicine at Albert Einstein College of Medicine, in New York City. While research from other countries has reported medications as a major culprit in anaphylaxis-related deaths, Jerschow said, the problem has been less defined in the United States. One reason is that there is no national registry for anaphylaxis deaths, she said. The study was ... Read more

Related support groups: Provera, Depo-Provera, Amoxicillin, Metronidazole, Doxycycline, Cephalexin, Clindamycin, Penicillin, Methotrexate, Azithromycin, Bactrim, Cipro, Ciprofloxacin, Accutane, Augmentin, Levaquin, Lupron, Flagyl, Keflex, Zithromax

Newer Drug Helps Myeloma Patients Who Can't Have Transplant

Posted 3 Sep 2014 by Drugs.com

WEDNESDAY, Sept. 3, 2014 – A cancer drug that targets the immune system may help improve the outlook for older adults with multiple myeloma, though a stem cell transplant remains the standard of care for relatively younger patients. Those are some of the findings from two studies in the Sept. 4 issue of the New England Journal of Medicine. Multiple myeloma is a cancer that begins in certain white blood cells. In the United States, it accounts for about 1 percent of cancers, and for those who develop it, it's often deadly. About 45 percent of Americans with the disease are still alive five years after diagnosis, according to the U.S. National Cancer Institute. For years, the standard treatment – at least for patients younger than 65 – has involved removing blood-forming stem cells from the patient's bone marrow or bloodstream, then using high-dose chemo to kill off the myeloma cells. ... Read more

Related support groups: Prednisone, Dexamethasone, Multiple Myeloma, Revlimid, Decadron, Thalidomide, Deltasone, Lenalidomide, Thalomid, Alkeran, Decadron Tablets, Rayos, Decadron Dose Pack, Liquid Pred, Sterapred, Dexone, Adrenocot, Dexpak Taperpak, Melphalan, Sterapred DS

FDA Approves Revlimid (lenalidomide) for the Treatment of Patients with Relapsed or Refractory Mantle Cell Lymphoma

Posted 5 Jun 2013 by Drugs.com

SUMMIT, N.J.--(BUSINESS WIRE)--Jun. 5, 2013-- Celgene Corporation today announced the U.S. Food and Drug Administration (FDA) has approved the company’s supplemental new drug application (sNDA) for Revlimid (lenalidomide) for the treatment of patients with mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib. “There remains a tremendous unmet need for patients with previously-treated mantle cell lymphoma,” said Andre Goy, M.D., M.S., Chairman and Director and Chief of Lymphoma, John Theurer Cancer Center at Hackensack UMC and Chief Science Officer and Director of Research and Innovation at Regional Cancer Care Associates, LLC. “The approval of lenalidomide delivers a new option, and the first oral therapy in this area of lymphoma.” The approval was based on the results of MCL-001, a phase II, multi-center, singl ... Read more

Related support groups: Lymphoma, Revlimid, Lenalidomide, Lymphoma, Non-Hodgkin's

Cancer Chemotherapy Tied to Slight Rise in Risk for Leukemia

Posted 14 Feb 2013 by Drugs.com

THURSDAY, Feb. 14 – Chemotherapy can be a lifesaver for thousands of cancer patients, but a new study suggests that it might slightly raise the odds for a type of leukemia later in life. Over the past 30 years, the risk for acute myeloid leukemia (AML) has increased for patients who underwent chemotherapy for certain forms of cancer, particularly non-Hodgkin lymphoma, the new study found. On the other hand, the researchers from the U.S. National Cancer Institute said other cancer survivors may have a reduced risk for AML due to a change in chemotherapy agents that occurred decades ago. One expert not connected to the study stressed that cancer patients need to put the findings into perspective. "It's important to realize that the risk of developing acute myeloid leukemia related to prior chemotherapy is small and increases with the number of chemotherapy treatments given over time," ... Read more

Related support groups: Cancer, Provera, Depo-Provera, Methotrexate, Accutane, Lupron, Tamoxifen, Medroxyprogesterone, Arimidex, Tretinoin, Fluorouracil, Femara, Lupron Depot, Gleevec, Isotretinoin, Rituxan, Claravis, Votrient, Anastrozole, Tarceva

New Drug Shows Promise for Myeloma Patients

Posted 9 May 2012 by Drugs.com

WEDNESDAY, May 9 – Three new studies confirm that the drug lenalidomide can significantly lengthen the time that people with multiple myeloma experience no worsening of their disease, either after having a stem cell transplant or getting chemotherapy. However, what isn't clear from the studies is whether or not the improved "progression-free" survival time will translate to a longer overall survival. "These are very promising, early studies," said the author of an accompanying editorial, Dr. Ashraf Badros, a professor in the department of medicine at the University of Maryland School of Medicine, in Baltimore. "I think these studies will generate a lot of discussion." Potential areas of debate, he said, include whether or not progression-free survival is enough if there isn't an overall survival benefit. He said that progression-free survival may well justify this treatment if quality ... Read more

Related support groups: Revlimid, Multiple Myeloma, Lenalidomide

FDA Medwatch Alert: Revlimid (lenalidomide): Ongoing Safety Review - Increased Risk of Developing New Malignancies

Posted 7 May 2012 by Drugs.com

[UPDATED 05/07/2012]  FDA notified the public of an increased risk of second primary malignancies (new types of cancer) in patients with newly-diagnosed multiple myeloma who received Revlimid (lenalidomide). Clinical trials conducted after Revlimid was approved showed that newly-diagnosed patients treated with Revlimid had an increased risk of developing second primary malignancies compared to similar patients who received a placebo. Specifically, these trials showed there was an increased risk of developing acute myelogenous leukemia, myelodysplastic syndromes, and Hodgkin lymphoma. This safety information has been added to the Warnings and Precautions section of the Revlimid drug label. The patient Medication Guide is also being updated to inform patients about this risk. Healthcare professionals should consider both the potential benefit of Revlimid and the risk of second primary m ... Read more

Related support groups: Revlimid, Multiple Myeloma, Lenalidomide

Cancer Patients Should Ask Doctors to Use Simple Terms

Posted 28 Sep 2011 by Drugs.com

WEDNESDAY, Sept. 28 – Cancer patients are often faced with many difficult-to-understand treatment choices that can have serious side effects and even mean the difference between life and death. That's why it's crucial that patients insist doctors use plain language in explaining the options, advised Angela Fagerlin, an associate professor of internal medicine at the University of Michigan Medical School and a researcher at the U-M Comprehensive Cancer Center. "People are making life and death decisions that may affect their survival and they need to know what they're getting themselves into. Cancer treatments and tests can be serious. Patients need to know what kind of side effects they might experience as a result of the treatment they undergo," Fagerlin said in a university news release. She and her colleagues outlined a number of tips to help patients get the information they need ... Read more

Related support groups: Cancer, Provera, Depo-Provera, Methotrexate, Breast Cancer, Accutane, Lupron, Prostate Cancer, Tamoxifen, Medroxyprogesterone, Arimidex, Tretinoin, Fluorouracil, Femara, Lupron Depot, Gleevec, Lung Cancer, Renal Cell Carcinoma, Colorectal Cancer, Isotretinoin

Page 1 2 Next

Ask a Question

Further Information

Related Condition Support Groups

Multiple Myeloma, Myelodysplastic Diseases, Lymphoma, Anemia, Mantle Cell Lymphoma

Revlimid Patient Information at Drugs.com